These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38127586)

  • 61. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
    Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
    TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
    [No Abstract]   [Full Text] [Related]  

  • 62. Acute treatment of intracranial hemorrhage complicated by hemophilia a and emicizumab therapy.
    Clark K; Patrick BM; Torian SC
    Am J Emerg Med; 2024 Feb; 76():272.e1-272.e2. PubMed ID: 38123423
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
    Shimonishi N; Sasai K; Ogiwara K; Furukawa S; Nakajima Y; Mizumachi K; Yada K; Takeyama M; Shima M; Mizuno N; Nogami K
    Int J Hematol; 2023 Dec; 118(6):690-698. PubMed ID: 37803190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
    Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
    EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
    Wall C; Xiang H; Palmer B; Chalmers E; Chowdary P; Collins PW; Fletcher S; Hall GW; Hart DP; Mathias M; Sartain P; Shapiro S; Stephensen D; Talks K; Hay CRM;
    Haemophilia; 2023 May; 29(3):743-752. PubMed ID: 36811304
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
    Pipe SW; Trzaskoma B; Minhas M; Lehle M; Ko RH; Gao L; Mahlangu J; Kempton CL; Kessler CM; Kruse-Jarres R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100077. PubMed ID: 36908770
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Emicizumab for All Pediatric Patients with Severe Hemophilia A.
    Wieland I
    Hamostaseologie; 2022 Apr; 42(2):104-115. PubMed ID: 35488163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
    Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
    Barg AA; Livnat T; Budnik I; Avishai E; Brutman-Barazani T; Tamarin I; Bashari D; Misgav M; Kenet G
    Br J Haematol; 2020 Oct; 191(2):282-290. PubMed ID: 32656767
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
    Escobar M; Bullano M; Mokdad AG; Caicedo J; Schultz BG; Fan Q; Verma S
    Expert Rev Hematol; 2023 Jun; 16(6):467-474. PubMed ID: 37114481
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 75. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry.
    van der Zwet K; de Kovel M; Motwani J; van Geet C; Nolan B; Glosli H; Escuriola Ettingshausen C; Königs C; Kenet G; Fischer K;
    Haemophilia; 2024 May; 30(3):685-692. PubMed ID: 38578720
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
    Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis.
    Prudente TP; Camelo RM; Guimarães RA; Roberti MDRF
    Sao Paulo Med J; 2024; 142(5):e2023102. PubMed ID: 38747872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.